FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956335962> ?p ?o ?g. }

• W2956335962 endingPage "1084" @default.
• W2956335962 startingPage "1082" @default.
• W2956335962 abstract "Cardiovascular disease disproportionately affects patients with chronic kidney disease (CKD) compared with the remainder of the population. In fact, CKD has historically been considered a cardiovascular disease “risk equivalent” along with other well known risk factors such as diabetes mellitus and peripheral vascular disease.1Sarnak M.J. Levey A.S. Schoolwerth A.C. et al.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Circulation. 2003; 108: 2154-2169Crossref PubMed Scopus (2822) Google Scholar Moreover, there is a clear “dose-response” relationship with more advanced stages of CKD associated with progressively higher rates of cardiovascular disease.2Go A.S. Chertow G.M. Fan D. McCulloch C.E. Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med. 2004; 351: 1296-1305Crossref PubMed Scopus (8722) Google Scholar The explanation for the heightened cardiovascular risk among the CKD population is multifactorial. There is substantial overlap among the underlying conditions that predispose to cardiovascular disease and CKD such as diabetes mellitus, hypertension, and vasculitis. Beyond these shared predisposing conditions, complications of CKD such as volume overload, anemia, and dysregulated bone and mineral metabolism further heighten cardiovascular risk among the CKD population.3Astor B.C. Arnett D.K. Brown A. Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study.Am J Kidney Dis. 2004; 43: 836-845Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar, 4Paloian N.J. Giachelli C.M. A current understanding of vascular calcification in CKD.Am J Physiol Renal Physiol. 2014; 307: F891-F900Crossref PubMed Scopus (199) Google Scholar, 5Tsai Y.C. Chiu Y.W. Tsai J.C. et al.Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD.Clin J Am Soc Nephrol. 2015; 10: 39-46Crossref PubMed Scopus (89) Google Scholar Currently measured primarily among symptomatic individuals, there has been a growing body of evidence showing that cardiac biomarkers, such as high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP), are predictive of future cardiovascular events among asymptomatic individuals in the general population.6de Lemos J.A. Drazner M.H. Omland T. et al.Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.JAMA. 2010; 304: 2503-2512Crossref PubMed Scopus (825) Google Scholar, 7Linssen G.C. Bakker S.J. Voors A.A. et al.N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.Eur Heart J. 2010; 31: 120-127Crossref PubMed Scopus (97) Google Scholar, 8Saunders J.T. Nambi V. de Lemos J.A. et al.Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.Circulation. 2011; 123: 1367-1376Crossref PubMed Scopus (551) Google Scholar, 9Wang T.J. Larson M.G. Levy D. et al.Plasma natriuretic peptide levels and the risk of cardiovascular events and death.N Engl J Med. 2004; 350: 655-663Crossref PubMed Scopus (1220) Google Scholar This raises the possibility of using these biomarkers to generate prognostic models for predicting future cardiovascular risk. Because of the substantially heightened cardiovascular risk among the CKD population, important issues to address are: (1) the prognostic value of these biomarkers in the setting of CKD; and (2) whether different thresholds for these biomarkers should be used in the CKD vs the non-CKD population. Interpretation of cardiac biomarkers in the CKD population represents a common challenge for the clinician. Among asymptomatic individuals, CKD patients generally have higher levels of hs-cTnT and NT-proBNP compared with the non-CKD population. Additionally, the more advanced the CKD, the higher the levels of these biomarkers even among asymptomatic patients.10Dubin R.F. Li Y. He J. et al.Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).BMC Nephrol. 2013; 14: 229Crossref PubMed Scopus (94) Google Scholar, 11Takase H. Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship.Eur J Clin Invest. 2014; 44: 303-308Crossref PubMed Scopus (71) Google Scholar The reasons behind the elevations in hs-cTnT and NT-proBNP are likely multifactorial. First, reduced renal clearance might contribute to elevation in each of these biomarkers.12de Lemos J.A. McGuire D.K. Drazner M.H. B-type natriuretic peptide in cardiovascular disease.Lancet. 2003; 362: 316-322Abstract Full Text Full Text PDF PubMed Scopus (891) Google Scholar, 13Tsutamoto T. Kawahara C. Yamaji M. et al.Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure.Eur J Heart Fail. 2009; 11: 653-658Crossref PubMed Scopus (68) Google Scholar Second, these cardiac biomarkers in the CKD population might signify the presence of subclinical levels of myocardial ischemia and cardiac volume overload.14Ooi D.S. Isotalo P.A. Veinot J.P. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology.Clin Chem. 2000; 46: 338-344Crossref PubMed Scopus (156) Google Scholar, 15DeFilippi C.R. Fink J.C. Nass C.M. Chen H. Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis.Am J Kidney Dis. 2005; 46: 35-44Abstract Full Text Full Text PDF PubMed Scopus (93) Google Scholar These differences in baseline values of hs-cTnT and NT-proBNP in CKD vs non-CKD patients ultimately make clinical interpretation of their prognostic meaning extremely challenging. Key questions that remain include: Should different thresholds for hs-cTnT and NT-proBNP be used in CKD? Should these thresholds vary further according to CKD stage? The article in this issue of the Canadian Journal of Cardiology by Canney et al. explores different thresholds for hs-cTnT and NT-proBNP by degree of CKD in regard to cardiovascular risk prognostication.16Canney M. Tang M. Er L. Barbour S.J. Djurdjev O. Levin A. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease.Can J Cardiol. 2019; 35: 1106-1113Google Scholar The authors performed a retrospective analysis from the Canadian study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time (CanPREDDICT) cohort. CanPREDDICT was a unique multicentre prospective cohort of individuals with nondialysis CKD with baseline estimated glomerular filtration rate (eGFR) between 15 and 45 mL/min/1.73 m2.17Levin A. Rigatto C. Brendan B. et al.Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT).BMC Nephrol. 2013; 14: 121Crossref PubMed Scopus (49) Google Scholar These participants had hs-cTnT and NT-proBNP measured at baseline and were followed for a median of 4 years. Adjudicated information on cardiovascular outcomes including acute coronary syndrome (unstable angina or myocardial infarction), congestive heart failure, stroke, and cardiovascular death was collected. Participants were stratified according to the degree of CKD at the time of study entry on the basis of baseline eGFR category: < 20, 20-29, or 30-44 mL/min/1.73 m2. Of 1956 participants from CanPREDDICT, a total of 401 cardiovascular events occurred during the study period.16Canney M. Tang M. Er L. Barbour S.J. Djurdjev O. Levin A. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease.Can J Cardiol. 2019; 35: 1106-1113Google Scholar In accordance with previous studies,6de Lemos J.A. Drazner M.H. Omland T. et al.Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.JAMA. 2010; 304: 2503-2512Crossref PubMed Scopus (825) Google Scholar, 7Linssen G.C. Bakker S.J. Voors A.A. et al.N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.Eur Heart J. 2010; 31: 120-127Crossref PubMed Scopus (97) Google Scholar, 8Saunders J.T. Nambi V. de Lemos J.A. et al.Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.Circulation. 2011; 123: 1367-1376Crossref PubMed Scopus (551) Google Scholar, 9Wang T.J. Larson M.G. Levy D. et al.Plasma natriuretic peptide levels and the risk of cardiovascular events and death.N Engl J Med. 2004; 350: 655-663Crossref PubMed Scopus (1220) Google Scholar, 10Dubin R.F. Li Y. He J. et al.Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).BMC Nephrol. 2013; 14: 229Crossref PubMed Scopus (94) Google Scholar, 11Takase H. Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship.Eur J Clin Invest. 2014; 44: 303-308Crossref PubMed Scopus (71) Google Scholar levels of hs-cTnT and NT-proBNP showed a stepwise increased association with: (1) severity of CKD; and (2) risk of future cardiovascular events. Unique to this study, the investigators assessed what the optimal cut point was for each level of CKD with regard to cardiovascular risk prognostication. They defined “standard” cutoffs for hs-cTnT and NT-proBNP as 14 ng/L and 125 pg/mL, respectively. It is worth mentioning that these are generally considered cutoffs for diagnostic purposes (eg, acute myocardial infarction or acute heart failure exacerbation) rather than for prognostic purposes,18Januzzi J.L. van Kimmenade R. Lainchbury J. et al.NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.Eur Heart J. 2006; 27: 330-337Crossref PubMed Scopus (823) Google Scholar, 19Kavsak P.A. Worster A. Ma J. et al.High-sensitivity cardiac troponin risk cutoffs for acute cardiac outcomes at emergency department presentation.Can J Cardiol. 2017; 33: 898-903Abstract Full Text Full Text PDF PubMed Scopus (17) Google Scholar as was the current study’s16Canney M. Tang M. Er L. Barbour S.J. Djurdjev O. Levin A. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease.Can J Cardiol. 2019; 35: 1106-1113Google Scholar focus. Nevertheless, the optimal prognostic cutoff for hs-cTnT increased in a stepwise fashion on the basis of the degree of baseline CKD: 22.7 ng/L for eGFR 30-44 mL/min/1.73 m2, 26.8 ng/L for eGFR 20-29 mL/min/1.73 m2, and 35.5 ng/L for eGFR < 20 mL/min/1.73 m2. This relationship between degree of baseline CKD and optimal prognostic cutoff was less clear for NT-proBNP using the following optimal cutoffs: 584 pg/mL for eGFR 30-44 mL/min/1.73 m2, 459 pg/mL for eGFR 20-29 mL/min/1.73 m2, and 765 pg/mL for eGFR < 20 mL/min/1.73 m2. Using these prognostic eGFR-specific cutoffs, as opposed to the aforementioned existing cutoffs for these cardiac biomarkers, not only improved the C-statistic of their prognostic models but also appropriately reclassified a large percentage of participants who experienced a cardiovascular event as being at “high risk” and those who did not as being at “low risk.” The findings by Canney et al.16Canney M. Tang M. Er L. Barbour S.J. Djurdjev O. Levin A. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease.Can J Cardiol. 2019; 35: 1106-1113Google Scholar add to the existing literature showing that baseline levels of hs-cTnT and NT-proBNP associate with future incident cardiovascular disease.20Bansal N. Hyre Anderson A. Yang W. et al.High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.J Am Soc Nephrol. 2015; 26: 946-956Crossref PubMed Scopus (79) Google Scholar The demonstrated optimal cutoffs for each of these biomarkers (when used for prognostic purposes) were found to vary according to severity of underlying CKD. These results beg the question of whether CKD, and its severity, should be incorporated into existing cardiovascular risk prediction models. Alternatively, do CKD patients fundamentally differ so much with regard to cardiac risk that they warrant their own CKD-specific risk prediction tools? Key areas for future study are to determine whether cardiac (eg, blood pressure control, lipid-lowering interventions, etc) and kidney risk reduction strategies (eg, antiproteinuric therapies) might be effective in reducing levels of these cardiac biomarkers, which might potentially signify an improved future cardiovascular risk profile. In other words, can we intervene when we discover elevations in these cardiac biomarkers to make a long-term difference in cardiovascular risk? Finally, Canney et al. focused on the prognostic cutoffs for hs-cTnT and NT-proBNP in asymptomatic individuals.16Canney M. Tang M. Er L. Barbour S.J. Djurdjev O. Levin A. Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease.Can J Cardiol. 2019; 35: 1106-1113Google Scholar Far more commonly, these biomarkers are used for diagnostic purposes in the settings of acute coronary syndrome or a heart failure exacerbation. Identifying what the optimal diagnostic cutoffs are (according to CKD severity) for these biomarkers in the acute setting might have a much more direct effect on medical practice. The authors have no conflicts of interest to disclose. Glomerular Filtration Rate-Specific Cutoffs Can Refine the Prognostic Value of Circulating Cardiac Biomarkers in Advanced Chronic Kidney DiseaseCanadian Journal of CardiologyVol. 35Issue 9PreviewUsing standard cutoffs derived from healthy adults, high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are frequently elevated in patients with reduced glomerular filtration rate (GFR), with unclear implications. We sought to compare GFR-specific cutoffs of each biomarker with standard cutoffs for discrimination of cardiovascular risk in asymptomatic patients with chronic kidney disease. Full-Text PDF" @default.
• W2956335962 created "2019-07-23" @default.
• W2956335962 creator A5036326268 @default.
• W2956335962 creator A5063670543 @default.
• W2956335962 date "2019-09-01" @default.
• W2956335962 modified "2023-09-23" @default.
• W2956335962 title "Is It Time to Recalibrate Cardiac Prediction Tools to Accommodate Chronic Kidney Disease?" @default.
• W2956335962 cites W1986122868 @default.
• W2956335962 cites W1995129939 @default.
• W2956335962 cites W2001090115 @default.
• W2956335962 cites W2009826381 @default.
• W2956335962 cites W2034530740 @default.
• W2956335962 cites W2044446185 @default.
• W2956335962 cites W2049893341 @default.
• W2956335962 cites W2076335162 @default.
• W2956335962 cites W2114089832 @default.
• W2956335962 cites W2120309176 @default.
• W2956335962 cites W2129285632 @default.
• W2956335962 cites W2139838444 @default.
• W2956335962 cites W2145632027 @default.
• W2956335962 cites W2151434193 @default.
• W2956335962 cites W2162625952 @default.
• W2956335962 cites W2167504169 @default.
• W2956335962 cites W2171427920 @default.
• W2956335962 cites W2256869561 @default.
• W2956335962 cites W2611840318 @default.
• W2956335962 cites W2950785803 @default.
• W2956335962 doi "https://doi.org/10.1016/j.cjca.2019.06.026" @default.
• W2956335962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31472806" @default.
• W2956335962 hasPublicationYear "2019" @default.
• W2956335962 type Work @default.
• W2956335962 sameAs 2956335962 @default.
• W2956335962 citedByCount "0" @default.
• W2956335962 crossrefType "journal-article" @default.
• W2956335962 hasAuthorship W2956335962A5036326268 @default.
• W2956335962 hasAuthorship W2956335962A5063670543 @default.
• W2956335962 hasBestOaLocation W29563359621 @default.
• W2956335962 hasConcept C126322002 @default.
• W2956335962 hasConcept C164705383 @default.
• W2956335962 hasConcept C177713679 @default.
• W2956335962 hasConcept C2778653478 @default.
• W2956335962 hasConcept C71924100 @default.
• W2956335962 hasConceptScore W2956335962C126322002 @default.
• W2956335962 hasConceptScore W2956335962C164705383 @default.
• W2956335962 hasConceptScore W2956335962C177713679 @default.
• W2956335962 hasConceptScore W2956335962C2778653478 @default.
• W2956335962 hasConceptScore W2956335962C71924100 @default.
• W2956335962 hasIssue "9" @default.
• W2956335962 hasLocation W29563359621 @default.
• W2956335962 hasLocation W29563359622 @default.
• W2956335962 hasOpenAccess W2956335962 @default.
• W2956335962 hasPrimaryLocation W29563359621 @default.
• W2956335962 hasRelatedWork W2011347913 @default.
• W2956335962 hasRelatedWork W2049397185 @default.
• W2956335962 hasRelatedWork W2074833529 @default.
• W2956335962 hasRelatedWork W2159512267 @default.
• W2956335962 hasRelatedWork W2304633692 @default.
• W2956335962 hasRelatedWork W2399063111 @default.
• W2956335962 hasRelatedWork W2920090081 @default.
• W2956335962 hasRelatedWork W3003571257 @default.
• W2956335962 hasRelatedWork W3092419277 @default.
• W2956335962 hasRelatedWork W1556208436 @default.
• W2956335962 hasVolume "35" @default.
• W2956335962 isParatext "false" @default.
• W2956335962 isRetracted "false" @default.
• W2956335962 magId "2956335962" @default.
• W2956335962 workType "article" @default.